The significant 1,25VD3-induced up-regulation of FBP1 to suppress glycolysis and its co-expression with VDR provides an important clinical implication that FBP1 could be a novel therapeutic target for the treatment of AML/its relapse by bypassing the impaired or low baseline VDR expression. This evidence concerns the gene FBP1 and acute myeloid leukemia.